Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

NEO-FRADIN

NEOMYCIN SULFATE

Standard Dose
EQ 87.5MG BASE/5ML
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview NEO-FRADIN is listed in Drugs@FDA under application 065010 (ANDA).

Marketing status: Discontinued Active ingredient NEOMYCIN SULFATE Form and strength SOLUTION;ORAL - EQ 87.5MG BASE/5ML Sponsor X GEN PHARMS Submission history Latest submission status date: 2012-01-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEO-FRADIN is listed in Drugs@FDA under application 065010 (ANDA). Marketing status: Discontinued Active ingredient NEOMYCIN SULFATE Form and strength SOLUTION;ORAL - EQ 87.5MG BASE/5ML Sponsor X GEN PHARMS Submission history Latest submission status date: 2012-01-17 00:00:00. Submission type: SUPPL.

Monitoring

  • • Review priority: UNKNOWN
  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
NEO-FRADIN (NEOMYCIN SULFATE) | Drug Monograph | MedicHelpline